JACLYN SHAVER: Open Payments
NPI 1376825596 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$715 in 35 payments from 13 companies in 2025. Trend: 2023 $313 · 2024 $697 · 2025 $715
Food & beverage: $715
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 7 | $154 |
| AstraZeneca Pharmaceuticals LP | 6 | $101 |
| GlaxoSmithKline, LLC. | 1 | $86 |
| Merck Sharp & Dohme LLC | 4 | $83 |
| Lilly USA, LLC | 4 | $59 |
| Astellas Pharma US Inc | 4 | $58 |
| Stemline Therapeutics Inc. | 2 | $42 |
| Genmab U.S., Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $21 |
Products named: ENHERTU, KEYTRUDA, VERZENIO, Veozah, LYNPARZA, Orserdu, Tivdak, Phesgo.
Industry payments across OK — which companies pay providers there.
